Arbutus Biopharma Shares Jump as Patent Dispute with Moderna Heads to Jury Trial

Arbutus Biopharma's stock is up 10% after a federal judge in Delaware ruled that a patent dispute involving Moderna's mRNA COVID-19 vaccine should be settled in a jury trial. The dispute centers on technology used in the vaccine, and the ruling means that the case will proceed to a jury trial instead of being resolved by the judge alone.